Sign in

Endometrial cancer: trials that stopped early

Trials on Endometrial cancer that stopped early, each with the reason the sponsor wrote in the registry, quoted word for word. Next to them: finished trials whose registry record links a result paper.

Stopped early

57 stopped trials give a reason in the registry, latest registry update first.

  1. Terminated

    PRO1107 in Patients With Advanced Solid Tumors

    Reason given in the registry

    “Genmab has decided to discontinue the clinical development of GEN1107 as the overall benefit-risk profile no longer supports continuation”

    Quoted unchanged from ClinicalTrials.gov; record updated 29 Oct 2026.

    Ended
    Aug 2025
    Phase
    Phase 1/2
    Run by
    Genmab
    Registry record
    NCT06171789
  2. Terminated

    Prospective Study of Detection of Sarcopenia in Clinical Practice for Patient With Ovarian or Endometrial Cancer

    Reason given in the registry

    “recruitement failure”

    Quoted unchanged from ClinicalTrials.gov; record updated 8 Oct 2026.

    Ended
    Aug 2024
    Run by
    Centre Hospitalier Metropole Savoie
    Registry record
    NCT05833321
  3. Terminated

    Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), and the RNR Inhibitor BBI-825, in Subjects With Tumors With Oncogene Amplifications

    Reason given in the registry

    “Decision was made to halt the study based on overall clinical experience and market considerations. This decision was not driven by any safety signal.”

    Quoted unchanged from ClinicalTrials.gov; record updated 19 Aug 2026.

    Ended
    Mar 2026
    Phase
    Phase 1
    Run by
    Boundless Bio, Inc.
    Registry record
    NCT05827614
  4. Terminated

    A Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Participants With Advanced Unresectable or Metastatic Solid Tumors

    Reason given in the registry

    “Following completion of Phase 1b, the Sponsor decided not to initiate Part 2 of the trial.”

    Quoted unchanged from ClinicalTrials.gov; record updated 13 Aug 2026.

    Ended
    Apr 2025
    Phase
    Phase 1/2
    Run by
    NextCure, Inc.
    Registry record
    NCT05572684
  5. Terminated

    GEN1047 for Solid Tumors - First in Human (FIH) Trial

    Reason given in the registry

    “The Sponsor has made a strategic decision to stop the development of GEN1047.”

    Quoted unchanged from ClinicalTrials.gov; record updated 23 Jul 2026.

    Ended
    Mar 2026
    Phase
    Phase 1/2
    Run by
    Genmab
    Registry record
    NCT05180474
  6. Terminated

    NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours

    Reason given in the registry

    “The NuTide:303 study was terminated at NuCana's discretion following refinement of the NUC-3373 development strategy.”

    Quoted unchanged from ClinicalTrials.gov; record updated 23 Jul 2026.

    Ended
    May 2025
    Phase
    Phase 1/2
    Run by
    NuCana plc
    Registry record
    NCT05714553
  7. Terminated

    The UPPROACH (Upfront Intensity Modulated Proton Beam Therapy) Approach

    Reason given in the registry

    “SOC changed and low enrollment”

    Quoted unchanged from ClinicalTrials.gov; record updated 8 Jul 2026.

    Ended
    Jul 2024
    Phase
    Phase 2
    Run by
    University of Maryland, Baltimore
    Registry record
    NCT04527900
  8. Terminated

    Weight Management Plus Megestrol Acetate in Early-stage Endometrioid Carcinoma

    Reason given in the registry

    “no enough enrolled patients”

    Quoted unchanged from ClinicalTrials.gov; record updated 4 Jun 2026.

    Ended
    Feb 2026
    Phase
    Phase 2/3
    Run by
    Xiaojun Chen
    Registry record
    NCT05316467
  9. Terminated

    Study of PF-07265807 in Participants With Metastatic Solid Tumors.

    Reason given in the registry

    “Pfizer has made an internal business decision to not continue further development of PF-07265807. This decision was not due to major safety concerns or requests from any regulatory authorities.”

    Quoted unchanged from ClinicalTrials.gov; record updated 4 Jun 2026.

    Ended
    Nov 2024
    Phase
    Phase 1
    Run by
    Pfizer
    Registry record
    NCT04458259
  10. Terminated

    Bevacizumab and/or Niraparib in Patients With Recurrent Endometrial and/or Ovarian Cancer With ARID1A Mutation

    Reason given in the registry

    “Funding issue”

    Quoted unchanged from ClinicalTrials.gov; record updated 3 Jun 2026.

    Ended
    Jan 2025
    Phase
    Phase 2
    Run by
    University of Oklahoma
    Registry record
    NCT05523440
  11. Withdrawn

    AssociatiNG Bevacizumab bEmarituzumab for GynecoLogIcal CAncer

    Reason given in the registry

    “Molecule not available from the laboratory”

    Quoted unchanged from ClinicalTrials.gov; record updated 23 Apr 2026.

    Phase
    Phase 1/2
    Run by
    Centre Leon Berard
    Registry record
    NCT07146919
  12. Terminated

    A Phase II Study of Futibatinib and Pembrolizumab in Metastatic Microsatellite Stable Endometrial Carcinoma

    Reason given in the registry

    “PI request”

    Quoted unchanged from ClinicalTrials.gov; record updated 27 Mar 2026.

    Ended
    May 2025
    Phase
    Phase 2
    Run by
    M.D. Anderson Cancer Center
    Registry record
    NCT05036681
  13. Terminated

    First-in-Human Study of ATX-559, an Oral Inhibitor of DHX9, in Patients With Advanced or Metastatic Solid Tumors, and Molecularly Defined Cancers

    Reason given in the registry

    “The study was terminated by sponsor based on the adverse event profile.”

    Quoted unchanged from ClinicalTrials.gov; record updated 24 Feb 2026.

    Ended
    Jan 2026
    Phase
    Phase 1
    Run by
    Accent Therapeutics
    Registry record
    NCT06625515
  14. Suspended

    Study of the CDK4/6 Inhibitor Palbociclib (PD-0332991) in Combination With the PI3K/mTOR Inhibitor Gedatolisib (PF-05212384) for Patients With Advanced Squamous Cell Lung, Pancreatic, Head & Neck and Other Solid Tumors

    Reason given in the registry

    “Funding and drug supply to continue the study are pending.”

    Quoted unchanged from ClinicalTrials.gov; record updated 13 Feb 2026.

    Phase
    Phase 1
    Run by
    Dana-Farber Cancer Institute
    Registry record
    NCT03065062
  15. Withdrawn

    Virtual Mental Health Intervention to Address Fear of Progression for Women With High Risk or Stage III-IV Gynecologic or Breast Cancer

    Reason given in the registry

    “slow accrual”

    Quoted unchanged from ClinicalTrials.gov; record updated 4 Feb 2026.

    Ended
    Jul 2026
    Run by
    City of Hope Medical Center
    Registry record
    NCT07226102
  16. Withdrawn

    Quality of Life Assessment of Radiotherapy in Recurrent Head and Neck Cancer

    Reason given in the registry

    “Study withdrawn due to lack of accrual.”

    Quoted unchanged from ClinicalTrials.gov; record updated 3 Feb 2026.

    Ended
    Jun 2025
    Run by
    University of Oklahoma
    Registry record
    NCT05850663
  17. Terminated

    A Study of PHN-010 in Patients With Advanced Solid Tumors

    Reason given in the registry

    “The study was terminated by Sponsor for strategic reasons.”

    Quoted unchanged from ClinicalTrials.gov; record updated 29 Jan 2026.

    Ended
    Sept 2025
    Phase
    Phase 1
    Run by
    Pheon Therapeutics
    Registry record
    NCT06457997
  18. Terminated

    Sacituzumab Govitecan for Relapsed Ovarian, Endometrial, and Cervical Carcinomas

    Reason given in the registry

    “This protocol was terminated prematurely because the prior principal investigator departed the Institute without treating any participants.”

    Quoted unchanged from ClinicalTrials.gov; record updated 21 Jan 2026.

    Ended
    Jul 2025
    Phase
    Phase 2
    Run by
    National Cancer Institute (NCI)
    Registry record
    NCT06865677
  19. Terminated

    Efficacy and Safety of TQB2450 Injection Combined With Chemotherapy ± Anlotinib Hydrochloride Capsules for Advanced Endometrial Cancer or Sarcoma of Uterus.

    Reason given in the registry

    “Per sponsor request. Premature closure was not prompted by any safety or efficacy concerns.”

    Quoted unchanged from ClinicalTrials.gov; record updated 9 Jan 2026.

    Ended
    Nov 2025
    Phase
    Phase 2
    Run by
    Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
    Registry record
    NCT05481645
  20. Terminated

    Phase 2 Study of PI3K Inhibitor Copanlisib in Combination With Fulvestrant in Selected ER+ and/or PR+ Cancers With PI3K (PIK3CA, PIK3R1) and/or PTEN Alterations

    Reason given in the registry

    “Copanlisib development was discontinued by Bayer following withdrawal of copanlisib in relapsed follicular lymphoma in November 2023.”

    Quoted unchanged from ClinicalTrials.gov; record updated 9 Jan 2026.

    Ended
    Dec 2025
    Phase
    Phase 2
    Run by
    M.D. Anderson Cancer Center
    Registry record
    NCT05082025
  21. Terminated

    A Phase 1 Study of [225Ac]-FPI-1434 Injection

    Reason given in the registry

    “A strategic decision was made to discontinue the study and prioritize other programs within the portfolio. The study was not discontinued due to safety issues or adverse events related to FPI-1434, FPE-1547, or FPI-1175.”

    Quoted unchanged from ClinicalTrials.gov; record updated 7 Jan 2026.

    Ended
    Dec 2025
    Phase
    Phase 1
    Run by
    Fusion Pharmaceuticals Inc.
    Registry record
    NCT03746431
  22. Terminated

    Letrozole as Maintenance Therapy for Post-surgical Endometrial Cancer Patients With NSMP

    Reason given in the registry

    “No enough participants”

    Quoted unchanged from ClinicalTrials.gov; record updated 15 Dec 2025.

    Ended
    Dec 2025
    Phase
    Phase 2/3
    Run by
    Fudan University
    Registry record
    NCT05454358
  23. Terminated

    Study of ART0380 in Patients With Biologically Selected Solid Tumors

    Reason given in the registry

    “Sponsor decision, not for reasons affecting the benefit-risk balance.”

    Quoted unchanged from ClinicalTrials.gov; record updated 6 Nov 2025.

    Ended
    May 2025
    Phase
    Phase 2
    Run by
    Artios Pharma Ltd
    Registry record
    NCT05798611
  24. Terminated

    Niraparib in the Treatment of Patients With Advanced PALB2 Mutated Tumors

    Reason given in the registry

    “Recruitment challenges”

    Quoted unchanged from ClinicalTrials.gov; record updated 29 Oct 2025.

    Ended
    Aug 2024
    Phase
    Phase 2
    Run by
    Tempus AI
    Registry record
    NCT05169437
  25. Terminated

    Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Advanced Solid Tumors

    Reason given in the registry

    “A business decision was made to discontinue further enrollment. There were no safety concerns that contributed to this decision.”

    Quoted unchanged from ClinicalTrials.gov; record updated 16 Oct 2025.

    Ended
    Aug 2024
    Phase
    Phase 1
    Run by
    Incyte Corporation
    Registry record
    NCT04272034
  26. Withdrawn

    18-fluorofuranylnorprogesterone (FFNP) PET/MRI as a Potential Biomarker of Response to Progesterone Therapy

    Reason given in the registry

    “Drug cannot be produced and scanner down.”

    Quoted unchanged from ClinicalTrials.gov; record updated 14 Oct 2025.

    Phase
    Phase 2
    Run by
    UNC Lineberger Comprehensive Cancer Center
    Registry record
    NCT05483023
  27. Terminated

    Study of Lenvatinib w/ Pembro in Black Participants w/Mismatch Repair-Prof Recurrent Endometrial Cancer

    Reason given in the registry

    “Closed early due to low enrollment rates”

    Quoted unchanged from ClinicalTrials.gov; record updated 2 Oct 2025.

    Ended
    Oct 2024
    Phase
    Phase 2
    Run by
    Virginia Commonwealth University
    Registry record
    NCT05263492
  28. Terminated

    A Study With NKT3447 for Adults With Advanced/Metastatic Solid Tumors

    Reason given in the registry

    “This study was terminated as a result of Sponsor portfolio reprioritization.”

    Quoted unchanged from ClinicalTrials.gov; record updated 25 Sept 2025.

    Ended
    Apr 2025
    Phase
    Phase 1
    Run by
    NiKang Therapeutics, Inc.
    Registry record
    NCT06264921
  29. Terminated

    A First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab in Advanced HER2-Expressing Solid Tumors

    Reason given in the registry

    “Sponsor Decision”

    Quoted unchanged from ClinicalTrials.gov; record updated 15 Sept 2025.

    Ended
    Feb 2025
    Phase
    Phase 1/2
    Run by
    Bolt Biotherapeutics, Inc.
    Registry record
    NCT04278144
  30. Terminated

    BAT1308 in Combination With Platinum-containing Chemotherapy is Used for the First-line Treatment of Advanced or Recurrent dMMR Endometrial Cancer

    Reason given in the registry

    “Due to the adjustment of our company's research and development strategy, we are now prematurely terminating this project.”

    Quoted unchanged from ClinicalTrials.gov; record updated 14 Aug 2025.

    Ended
    Aug 2025
    Phase
    Phase 2/3
    Run by
    Bio-Thera Solutions
    Registry record
    NCT06321068

Sources: ClinicalTrials.gov and the EU Clinical Trials Register. Status, reason, dates and result links are registry fields, shown as the registry gives them.